These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Comparison of MR imaging and urodynamic findings in benign prostatic hyperplasia. Alam AM; Sugimura K; Okizuka H; Ishida J; Igawa M Radiat Med; 2000; 18(2):123-8. PubMed ID: 10888045 [TBL] [Abstract][Full Text] [Related]
48. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. Tubaro A; Carter S; Hind A; Vicentini C; Miano L J Urol; 2001 Jul; 166(1):172-6. PubMed ID: 11435849 [TBL] [Abstract][Full Text] [Related]
49. [Analysis of the diagnostic criteria of bladder outlet obstruction in benign prostatic hyperplasia]. Shuang W; Wang D; Zhang X; Liu C; Cao X; Wang J; Gao J; Ren Z; Lü Y Zhonghua Nan Ke Xue; 2004 Oct; 10(10):743-6. PubMed ID: 15562786 [TBL] [Abstract][Full Text] [Related]
51. Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate? Antunes AA; Iscaife A; Reis ST; Albertini A; Nunes MA; Lucon AM; Nahas WC; Srougi M J Urol; 2015 Jun; 193(6):2028-32. PubMed ID: 25583645 [TBL] [Abstract][Full Text] [Related]
52. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates. Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922 [TBL] [Abstract][Full Text] [Related]
53. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954 [TBL] [Abstract][Full Text] [Related]
54. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575 [TBL] [Abstract][Full Text] [Related]
55. [TULIP--transurethral ultrasound-controlled laser-induced prostatectomy: an alternative to TURP?]. Schulze H; Martin W; Engelmann U; Senge T Urologe A; 1993 May; 32(3):225-31. PubMed ID: 7685555 [TBL] [Abstract][Full Text] [Related]
56. [Transurethral laser ablation of the prostate (TULAP). Initial results with 188 patients]. Gottfried HW; Krautschick A; Hefty R; Weber HM; Frohneberg D; Hautmann RE Urologe A; 1995 Mar; 34(2):132-7. PubMed ID: 7538711 [TBL] [Abstract][Full Text] [Related]
57. Bipolar Button Transurethral Enucleation of Prostate in Benign Prostate Hypertrophy Treatment: A New Surgical Technique. Giulianelli R; Gentile B; Albanesi L; Tariciotti P; Mirabile G Urology; 2015 Aug; 86(2):407-13. PubMed ID: 26189138 [TBL] [Abstract][Full Text] [Related]
58. Influence of bladder outlet obstruction and detrusor contractility on residual urine in patients with benign prostatic hyperplasia. Zhang P; Wu Z; Gao J Chin Med J (Engl); 2003 Oct; 116(10):1508-10. PubMed ID: 14570611 [TBL] [Abstract][Full Text] [Related]
59. Animal models of bladder outlet obstruction and molecular insights into the basis for the development of bladder dysfunction. Buttyan R; Chen MW; Levin RM Eur Urol; 1997; 32 Suppl 1():32-9. PubMed ID: 9218941 [TBL] [Abstract][Full Text] [Related]
60. A possible use of color Doppler flow imaging in predicting the cause of bladder hypertrophy. Naya Y Tohoku J Exp Med; 1997 Jun; 182(2):139-50. PubMed ID: 9261932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]